Anti CD19 monoclonal antibody UPLIZNAⓇ for I.V. Infusion 100mg Application for additional indication of immunoglobulin G4 related disease in Japan［PDF:435.6 KB］

Mitsubishi Tanabe Pharma Corporation published this content on March 21, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on March 21, 2025 at 02:00 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]